Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity
Advanced Drug Delivery Reviews · 2025
DOI: 10.1016/j.addr.2025.115573 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025. Verfasst von Artur Galushkin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Diana and Zelman Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Faculty of Medical &…. Hauptthemen laut MEDLINE: Circadian Rhythm, Neuroprotective Agents, Neurodegenerative Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this review we examine the neuroprotective potential of NAP (davunetide), a small peptide derived from Activity-Dependent Neuroprotective Protein (ADNP), in the context of neurodevelopmental and neurodegenerative disorders. ADNP, a protein essential for brain development and function, is associated with tauopathy-related diseases, such as Alzheimer's Disease (AD), and circadian rhythm regulation. NAP enhances microtubule stability and prevents tauopathy. In preclinical studies, NAP shows promise in improving cognitive performance and correcting behavioral deficits in different models. Clinical studies on NAP (davunetide) administered via intranasal delivery have demonstrated its safety, favorable bioavailability, and potential efficacy in improving cognitive function, making it a viable therapeutic option. In the pure tauopathy, progressive supranuclear palsy, NAP (davunetide) significantly slowed disease progression in women in a phase II-III clinical trial. Additionally, the complex interactions between ADNP, associated pathways, and circadian regulation and the extensive NAP compensation upon ADNP deficiency attest to further clinical development. Thus, NAP is an example of a reductionist approach in drug delivery, replacing/enhancing the critical large ADNP-related pathways including dysregulated microtubules and tauopathy with a small brain bioavailable investigational drug, davunetide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Diana and Zelman Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Faculty of Medical & Health Sciences, Adams Super Center for Brain Studies and Sagol Schoo…
Zitieren
APA
Galushkin, A., & Gozes, I. (2025). Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2025.115573
Vancouver
Galushkin A, Gozes I. Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity. Advanced Drug Delivery Reviews. 2025. doi:10.1016/j.addr.2025.115573
BibTeX
@article{Galushkin2025,
author = {Galushkin, Artur and Gozes, Illana},
title = {Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
doi = {10.1016/j.addr.2025.115573}
}
EUVIMED